Table: Towa Pharmaceutical -2024/25 parent results
May 15 (Reuters)-
Towa Pharmaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2025 Mar 31, 2024 Mar 31, 2026 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 172.27 149.22
(+15.4 pct) (+20.3 pct)
Operating 23.69 19.96
(+18.7 pct) (+114.5 pct)
Recurring 27.53 27.23
(+1.1 pct) (+218.8 pct)
Net 21.10 19.60
(+7.7 pct) (+209.6 pct)
EPS 428.66 yen 398.21 yen
Ann Div 70.00 yen 60.00 yen 80.00 yen
-Q2 Div 30.00 yen 30.00 yen 40.00 yen
-Q4 Div 40.00 yen 30.00 yen 40.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results